Todd C. Girolamo
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Longeveron to speak at three longevity investment conferences. Longeveron has announced it will participate in three upcoming conferences focused on longevity and aging research. These events provide a platform for the company to discuss its scientific progress with investors and industry professionals. The stock is currently trading well below its 52-week high, with an average analyst target of $61.25.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Lisata reports first patient dose in MAR002 acromegaly trial. Lisata Therapeutics announced that its subsidiary Marea Therapeutics has given the first dose of MAR002 to a patient in a Phase 2 trial for acromegaly. This marks the first clinical exposure of the drug and represents a key step toward potential regulatory approval. The announcement highlights progress in Lisata’s development pipeline, though the company remains in early stages of product development.
Transaction History
| PROK | ▼ Sell | Other | 163,857 | $0 | 6/12/2026 | View on chart |
| PROK | ▼ Sell | Other | 81,928 | $0 | 7/31/2024 | View on chart |
| PROK | ▼ Sell | Other | 81,928 | $0 | 2/5/2024 | View on chart |
| LGVN | ▲ Buy | Grant | 5,000 | $0 | 2/25/2022 | View on chart |
| LSTA | ▼ Sell | Tax Withholding | 2,158 | $2K | 1/14/2022 | View on chart |
| LSTA | ▼ Sell | Tax Withholding | 2,563 | $2K | 1/13/2022 | View on chart |
| LSTA | ▼ Sell | Tax Withholding | 4,722 | $4K | 1/11/2022 | View on chart |
| LSTA | ▼ Sell | Tax Withholding | 17,405 | $16K | 1/10/2022 | View on chart |
| LSTA | ▲ Buy | Grant | 129,000 | $0 | 1/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
PROK: Eight ProKidney Abstracts Chosen for Kidney Week 2026
ProKidney Corp. announced that eight of its research abstracts were chosen to be presented at the American Society of Nephrology’s Kidney Week 2026. The selection highlights the company’s active research program in kidney disease. It shows that ProKidney’s work is gaining recognition from the nephrology community. The news may support the company’s long‑term development plans.
PROK: Eight ProKidney Abstracts Chosen for Kidney Week 2026. ProKidney Corp. announced that eight of its research abstracts were chosen to be presented at the American Society of Nephrology’s Kidney Week 2026. The selection highlights the company’s active research program in kidney disease. It shows that ProKidney’s work is gaining recognition from the nephrology community. The news may support the company’s long‑term development plans.